Effect of dezocine combined with dexmedetomidine on postoperative pain and quality of life in patients with advanced liver cancer

Abstract

To investigate the effect of dezocine injection combined with dexmedetomidine on pain and quality of life in patients with advanced hepatocellular carcinoma. 64 patients with advanced liver cancer undergone surgery in the Central Hospital of EnshiTujia and Miao Autonomous centre from January 2016 to January 2019 were selected and randomly assigned to the experimental group and the control group. The control group was anesthetized with remifentanil during the operation and the experimental group was given remifentanil along with a combination of dezocine combined with dexmedetomidine. After the anesthesia, the time of extubating and the recovery time of the 2 groups were monitored, the visual analogue scale was used to evaluate the degree of pain in both the groups of patients at 2, 6 and 24 h, respectively and the SF-36 dimensions of 7D before and after the surgery were scored for both the groups. The incidence of adverse reactions in both the groups of patients post-surgery were monitored and compared. The visual analogue scale scores of the experimental group were lower than those of the control group at 2, 6 and 24 h after surgery (p<0.05). The visual analogue scale scores at 6 and 24 h after surgery were statistically lower than those at 2 h after surgery. The extubation time, recovery time and orientation recovery time in the experimental group were all lower than those in the control group, the SF-36 dimension scores in both groups before the surgery were not significantly different. The scores of all dimensions in the experimental group were significantly higher than those in the control group post-surgery. The scores of physical function, mental function and life function significantly (p<0.05) increased after intervention in both the groups. The incidence of adverse reactions was lower in the experimental group compared to the control group (p<0.05). Dezocine injection combined with dexmedetomidine could significantly relieve postoperative pain in patients with advanced hepatocellular carcinoma, shorten the recovery time and improve the quality of life.